211 related articles for article (PubMed ID: 29600194)
1. Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers.
Soundararajan R; Aparicio AM; Logothetis CJ; Mani SA; Maity SN
Front Oncol; 2018; 8():69. PubMed ID: 29600194
[TBL] [Abstract][Full Text] [Related]
2. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
Nyquist MD; Corella A; Coleman I; De Sarkar N; Kaipainen A; Ha G; Gulati R; Ang L; Chatterjee P; Lucas J; Pritchard C; Risbridger G; Isaacs J; Montgomery B; Morrissey C; Corey E; Nelson PS
Cell Rep; 2020 May; 31(8):107669. PubMed ID: 32460015
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
Yamada Y; Beltran H
Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
[TBL] [Abstract][Full Text] [Related]
4. Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition.
Martin P; Liu YN; Pierce R; Abou-Kheir W; Casey O; Seng V; Camacho D; Simpson RM; Kelly K
Am J Pathol; 2011 Jul; 179(1):422-35. PubMed ID: 21703421
[TBL] [Abstract][Full Text] [Related]
5. Reprogramming hormone-sensitive prostate cancer to a lethal neuroendocrine cancer lineage by mitochondrial pyruvate carrier (MPC).
Xu H; Liu Z; Gao D; Li P; Shen Y; Sun Y; Xu L; Song N; Wang Y; Zhan M; Gao X; Wang Z
Mol Metab; 2022 May; 59():101466. PubMed ID: 35219875
[TBL] [Abstract][Full Text] [Related]
6. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.
Imamura J; Ganguly S; Muskara A; Liao RS; Nguyen JK; Weight C; Wee CE; Gupta S; Mian OY
Front Endocrinol (Lausanne); 2023; 14():1191311. PubMed ID: 37455903
[TBL] [Abstract][Full Text] [Related]
7. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S; Inoue T; Ogawa O; Gleave ME
Int J Urol; 2018 Apr; 25(4):345-351. PubMed ID: 29396873
[TBL] [Abstract][Full Text] [Related]
9. EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.
Soundararajan R; Paranjape AN; Maity S; Aparicio A; Mani SA
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):229-238. PubMed ID: 29981816
[TBL] [Abstract][Full Text] [Related]
10. Epithelial-Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics.
Chaves LP; Melo CM; Saggioro FP; Reis RBD; Squire JA
Genes (Basel); 2021 Nov; 12(12):. PubMed ID: 34946849
[TBL] [Abstract][Full Text] [Related]
11. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
12. Prostate tumor neuroendocrine differentiation via EMT: The road less traveled.
Dicken H; Hensley PJ; Kyprianou N
Asian J Urol; 2019 Jan; 6(1):82-90. PubMed ID: 30775251
[TBL] [Abstract][Full Text] [Related]
13. The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1.
Romero R; Chu T; González-Robles TJ; Smith P; Xie Y; Kaur H; Yoder S; Zhao H; Mao C; Kang W; Pulina MV; Lawrence KE; Gopalan A; Zaidi S; Yoo K; Choi J; Fan N; Gerstner O; Karthaus WR; DeStanchina E; Ruggles KV; Westcott PMK; Chaligné R; Pe'er D; Sawyers CL
bioRxiv; 2024 Apr; ():. PubMed ID: 38645223
[TBL] [Abstract][Full Text] [Related]
14. Role of MicroRNAs in Neuroendocrine Prostate Cancer.
Sreekumar A; Saini S
Noncoding RNA; 2022 Mar; 8(2):. PubMed ID: 35447888
[TBL] [Abstract][Full Text] [Related]
15. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.
Beltran H; Hruszkewycz A; Scher HI; Hildesheim J; Isaacs J; Yu EY; Kelly K; Lin D; Dicker A; Arnold J; Hecht T; Wicha M; Sears R; Rowley D; White R; Gulley JL; Lee J; Diaz Meco M; Small EJ; Shen M; Knudsen K; Goodrich DW; Lotan T; Zoubeidi A; Sawyers CL; Rudin CM; Loda M; Thompson T; Rubin MA; Tawab-Amiri A; Dahut W; Nelson PS
Clin Cancer Res; 2019 Dec; 25(23):6916-6924. PubMed ID: 31363002
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.
Conteduca V; Ku SY; Fernandez L; Dago-Rodriquez A; Lee J; Jendrisak A; Slade M; Gilbertson C; Manohar J; Sigouros M; Wang Y; Dittamore R; Wenstrup R; Mosquera JM; Schonhoft JD; Beltran H
NPJ Precis Oncol; 2021 Aug; 5(1):76. PubMed ID: 34385567
[TBL] [Abstract][Full Text] [Related]
17. Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention.
Nouri M; Ratther E; Stylianou N; Nelson CC; Hollier BG; Williams ED
Front Oncol; 2014; 4():370. PubMed ID: 25566507
[TBL] [Abstract][Full Text] [Related]
18. Cellular identity crisis: Antiandrogen resistance by lineage plasticity.
Tuerff D; Sissung T; Figg WD
Cancer Biol Ther; 2017 Nov; 18(11):841-842. PubMed ID: 28475401
[TBL] [Abstract][Full Text] [Related]
19. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo.
Zacharias N; Lee J; Ramachandran S; Shanmugavelandy S; McHenry J; Dutta P; Millward S; Gammon S; Efstathiou E; Troncoso P; Frigo DE; Piwnica-Worms D; Logothetis CJ; Maity SN; Titus MA; Bhattacharya P
Mol Imaging Biol; 2019 Feb; 21(1):86-94. PubMed ID: 29748904
[TBL] [Abstract][Full Text] [Related]
20. The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis.
Mei W; Lin X; Kapoor A; Gu Y; Zhao K; Tang D
Cancers (Basel); 2019 Mar; 11(4):. PubMed ID: 30934773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
